Small Business Innovation Research · Small Business Technology Transfer
L2 Diagnostics LLC: SBIR & STTR awards
94 awards worth $49.70M to 1 companies since 1999 match these filters. Phase I tests an idea (usually a few hundred thousand dollars); Phase II builds it (often $1M or more).
L2 Diagnostics LLC's federal contracts and grants · All SBIR & STTR awards
Awards by year
| Year | Phase I | Phase II | Amount |
|---|---|---|---|
| 2025 | 6 | 0 | $2.07M |
| 2024 | 4 | 0 | $2.40M |
| 2022 | 0 | 1 | $2.95M |
| 2021 | 1 | 0 | $599.0K |
| 2020 | 2 | 1 | $2.97M |
| 2019 | 4 | 0 | $2.37M |
| 2018 | 4 | 0 | $1.20M |
| 2017 | 3 | 1 | $3.09M |
| 2016 | 2 | 1 | $2.08M |
| 2015 | 2 | 0 | $568.5K |
| 2014 | 4 | 3 | $7.32M |
| 2013 | 1 | 0 | $595.4K |
The latest year fills in over months: agencies report awards to SBIR.gov with a lag.
Latest matching awards
| Award | Company | Agency | Phase | Amount | Date |
|---|---|---|---|---|---|
| A vaccine targeting mosquito metabolic pathways to eradicate malaria · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $299.6K | 2025-09-23 |
| A viral vector-based vaccine to induce humoral and cellular immune protection against Powassan virus in a tick transmission model · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $281.8K | 2025-09-23 |
| A Point of Care Test for Babesia microti · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $293.1K | 2025-09-21 |
| PfAg, a multivalent peptide vaccine against malaria · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $300.0K | 2025-09-15 |
| THERAPEUTIC VACCINE PLATFORM TO BOOST IMMUNE RESPONSES IN TUBERCULOSIS · topic 137 | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $599.5K | 2025 |
| Novel Diagnostic Biomarker Discovery and Validation for Malaria · topic 132 | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $300.0K | 2025 |
| The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $599.9K | 2024-07-17 |
| A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $599.9K | 2024-07-08 |
| Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $599.7K | 2024-06-01 |
| A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $597.6K | 2024-05-01 |
| A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase II | $2.95M | 2022-08-18 |
| A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1 · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $599.0K | 2021-08-04 |
| An antigen-detection assay to diagnose Babesia microti infection · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.08M | 2020-06-22 |
| Vaccination against Zika virus infection using mosquito NeSt1 protein · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $593.1K | 2020-06-16 |
| Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $298.9K | 2019-12-09 |
| Targets of Acquired Tick-Resistance As Anti-Tick Vaccines · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $596.6K | 2019-07-01 |
| Development of A Narrow Spectrum Anti-Tubercular Agent · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $585.3K | 2019-07-01 |
| Immunization with mosquito AgTRIO protein to prevent malaria · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $592.3K | 2019-04-16 |
| A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $594.2K | 2019-01-21 |
| Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus · topic NIAMS | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $225.0K | 2018-09-11 |
| Development of a Point of Care Diagnostic Screening test for Kawasaki disease · topic NICHD | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $225.0K | 2018-08-11 |
| Therapeutic Inhibition of MIF to Improve Glucocorticoid Response · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $453.4K | 2018-02-08 |
| An antigen-detection assay to diagnose Babesia microti infection · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $300.0K | 2018-01-10 |
| Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy · topic NIDDK | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $299.8K | 2017-09-15 |
| Validation of a Diagnostic Test for Borrelia miyamotoi · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $574.2K | 2017-08-14 |
| A Rapid Low Cost Point of Care Diagnostic for detection of Zika virus RNA · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $225.0K | 2017-02-01 |
| PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTRATE CANCER RADIOTHERAPY · topic NCI | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.00M | 2017 |
| Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy · topic NIAMS | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.48M | 2016-09-19 |
| Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $300.0K | 2016-07-15 |
| Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma · topic 102 | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $299.0K | 2016-03-01 |
| Therapeutic Inhibition of MIF in Type 1 Diabetes · topic 200 | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $297.3K | 2015-01-17 |
| IGF OT IGF Topic Phase I SBIR Predictive Biomarkers of Adverse Reactions to Prostate Cancer Radiotherapy · topic NCI | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $271.2K | 2015 |
| Measurement of Beta Cell Death in Diabetes · topic 200 | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase II | $1.35M | 2014-09-01 |
| A serologic assay to measure successful Lyme borreliosis antibiotic therapy · topic R | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.64M | 2014-07-01 |
| Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.66M | 2014-07-01 |
| RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $600.0K | 2014-07-01 |
| A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $600.0K | 2014-07-01 |
| Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $250.3K | 2014 |
| Sterculic Acid Analogs to Inhibit Macular Degeneration · topic NEI | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $224.7K | 2014 |
| A Lyme disease vaccine using newly identified in-vivo expressed antigens · topic NIAID | L2 Diagnostics LLC · Connecticut | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $595.4K | 2013 |
Source: SBIR.gov award data (SBA) ↗, awards through 2026-08-28. Amounts are as agencies report them to SBA. SBIR/STTR contracts also appear in USAspending as ordinary awards; grants (NIH, NSF, DOE) appear as assistance. Open topics are posted by each agency; see Opportunities for contract notices.